These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 5504553)

  • 21. [Efficacy and side effects of L-dopa in patients with Parkinson's syndrome].
    Lombardo L
    Arch Invest Med (Mex); 1973; 4(3):215-24. PubMed ID: 4784173
    [No Abstract]   [Full Text] [Related]  

  • 22. [Personal experience in the treatment of Parkinson's disease with L-Dopa].
    Figuerido JA; De la Herrán J
    Rev Clin Esp; 1970 Dec; 119(6):555-62. PubMed ID: 5509794
    [No Abstract]   [Full Text] [Related]  

  • 23. [L-dopa effect in Parkinson's syndrome].
    Römer F; Bettag W; Bock WJ
    Z Allgemeinmed; 1971 Feb; 47(6):281-3. PubMed ID: 5571715
    [No Abstract]   [Full Text] [Related]  

  • 24. [The therapeutic association of L-dopa and amantadine. Preliminary results in a group of patients with Parkinson's disease].
    Gomirato G; Perfetti C
    Riv Neurobiol; 1970; 16(3):247-54. PubMed ID: 5518838
    [No Abstract]   [Full Text] [Related]  

  • 25. [Silent period in patients with Parkinson's disease treated with L-Dopa].
    Palao Sánchez A
    Arch Neurobiol (Madr); 1973; 36(1):47-56. PubMed ID: 4706780
    [No Abstract]   [Full Text] [Related]  

  • 26. L-dopa treatment of parkinsonism. Clinical observations on the use of amantadine hydrochloride.
    Reveno WS; Bauer RB; Rosenbaum H
    Geriatrics; 1971 Aug; 26(8):61-70. PubMed ID: 5096462
    [No Abstract]   [Full Text] [Related]  

  • 27. Interactions of L-dopa and amantadine in patients with Parkinsonism.
    Cox B; Danta G; Schnieden H; Yuill GM
    J Neurol Neurosurg Psychiatry; 1973 Jun; 36(3):354-61. PubMed ID: 4714097
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Medical treatment of Parkinson's disease with amantadine hydrochloride. Preliminary note].
    Portera A; Varela de Seijas E; Mata P; Ramírez Echevarría TJ; Amaya Pombo C
    Rev Clin Esp; 1970 Jun; 117(6):579-86. PubMed ID: 5518942
    [No Abstract]   [Full Text] [Related]  

  • 29. [Current therapeutics of Parkinson's disease].
    Schott B
    Cah Med; 1971 Nov; 12(14):1175-85. PubMed ID: 5161038
    [No Abstract]   [Full Text] [Related]  

  • 30. [Amantadine in the treatment of Parkinson's disease].
    Giombini S; Solero CL; Bazzan A; Ferrari P; Robotti E
    Fracastoro; 1970; 63(6):869-81. PubMed ID: 5519639
    [No Abstract]   [Full Text] [Related]  

  • 31. [Treatment of Parkinson's disease with amantadine].
    Sigwald J; Raymondeaud C; Grégoire J
    Therapeutique; 1972 Nov; 48(9):555-60. PubMed ID: 4568230
    [No Abstract]   [Full Text] [Related]  

  • 32. [Effects of L-dopa or amantadine treatment on the spindles of sleep in Parkinson's syndromes].
    Puca FM; Bricolo A; Turella G
    Rev Neurol (Paris); 1972 Aug; 127(2):313. PubMed ID: 4666639
    [No Abstract]   [Full Text] [Related]  

  • 33. [Treatment of the Parkinson syndrome with amantadine].
    Hartmann-von Monakow K
    Schweiz Med Wochenschr; 1971 Dec; 101(48):1736-9. PubMed ID: 5140093
    [No Abstract]   [Full Text] [Related]  

  • 34. Combined treatment of parkinsonism with L-dopa and amantadine.
    Hunter KR; Stern GM; Laurence DR; Armitage P
    Lancet; 1970 Sep; 2(7672):566. PubMed ID: 4195220
    [No Abstract]   [Full Text] [Related]  

  • 35. [Clinical results of the intravenous administration of amantadine in patients with parkinsonism].
    Caliri F; Di Rosa AE; Meduri M; Megna G; Musolino R; Scuderi D
    Minerva Med; 1971 Oct; 62(82):3994-6. PubMed ID: 5125062
    [No Abstract]   [Full Text] [Related]  

  • 36. [Drug therapy of Parkinson's disease with amantadine and levodopa].
    Fieschi C; Nardini M; Casacchia M; Reitano M; Tedone ME; Ferrari P; Robotti E
    Sist Nerv; 1970; 22(2):126-43. PubMed ID: 5504552
    [No Abstract]   [Full Text] [Related]  

  • 37. Amino acid and dopa levels in plasma and urine from L-dopa-treated patients with Parkinson's disease.
    Hare TA; Vanna S; Beasley B; Chambers R; Vogel WH
    J Lab Clin Med; 1971 Feb; 77(2):319-25. PubMed ID: 5540775
    [No Abstract]   [Full Text] [Related]  

  • 38. [The addition of amantadine to prolonged treatment with L-Dopa. Considerations on 20 cases].
    Giuffrè R; Gambacorta D
    Minerva Med; 1971 Oct; 62(82):4009-12. PubMed ID: 5125066
    [No Abstract]   [Full Text] [Related]  

  • 39. The treatment of parkinsonism with L-Dopa and amantadine.
    Green J
    J Fla Med Assoc; 1970 Jun; 57(6):28-33. PubMed ID: 5445813
    [No Abstract]   [Full Text] [Related]  

  • 40. Amantadine versus L-2 dopa and amatadine plus L-dopa.
    Fieschi C; Nardini M; Casacchia M; Tedone ME; Reitano M; Robotti E
    Lancet; 1970 Jul; 2(7664):154-5. PubMed ID: 4194541
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.